Table 3.
Clinical Outcomes
|
Laparoscopic
(n=38) |
Robotic
(n=40) |
Treatmen t Effect P |
|||||
|---|---|---|---|---|---|---|---|
| Baselin e |
3 Months |
6 Months |
Baselin e |
3 Months |
6 Months |
||
| POP-Q (cm) Point Ba |
2.45 | −2.34 | −2.43 | 2.58 | −2.56 | −2.48 | 0.833 |
| (1.84) | (1.19) | (0.86) | (2.01) | (0.69) | (0.76) | ||
| POP-Q (cm) Point C |
0.74 | −7.74 | −7.30 | 0.25 | −7.89 | −7.97 | 0.502 |
| (3.64) | (4.74) | (6.04) | (3.98) | (5.05) | (4.37) | ||
| POPQ (cm) Point Bp |
0.21 | −2.66 | −2.63 | −0.50 | −2.17 | −2.33 | 0.977 |
| (3.05) | (0.59) | (0.67) | (2.94) | (1.48) | (1.22) | ||
| UDI* | 97.5 | 25.7 | 25.1 | 110.1 | 30.3 | 31.3 | 0.208 |
| (60.4) | (40.8) | (31.4) | (58.7) | (42.1) | (35.3) | ||
| POPDI* | 116.5 | 28.7 | 22.6 | 126.6 | 32.7 | 34.8 | 0.177 |
| (60.8) | (28.3) | (25.9) | (63.1) | (45.4) | (41.0) | ||
| CRADI* | 99.0 | 34.3 | 34.8 | 90.1 | 44.1 | 43.4 | 0.756 |
| (71.7) | (33.5) | (44.9) | (71.9) | (48.3) | (49.1) | ||
| UIQ* | 97.6 | 31.1 | 31.8 | 128.3 | 29.4 | 20.6 | 0.501 |
| (96.3) | (71.1) | (57.8) | (93.8) | (56.6) | (43.3) | ||
| CRAIQ* | 67.5 | 17.2 | 24.1 | 67.0 | 20.8 | 17.3 | 0.881 |
| (87.5) | (33.8) | (52.4) | (89.8) | (38.3) | (34.3) | ||
| POPIQ* | 83.2 | 17.2 | 9.4 | 114.4 | 14.7 | 14.6 | 0.181 |
| (83.7) | (59.7) | (36.1) | (102.4) | (33.5) | (39.4) | ||
POP-Q, pelvic organ prolapse quantification; UDI, Urinary Distress Inventory; POPDI, Pelvic Organ Prolapse Distress Inventory; CRADI, Colon Rectal Anal Distress Inventory; UIQ, Urinary Impact Questionnaire; CRAIG, Colon Rectal Anal Impact Questionnaire; POPIQ, Pelvic Organ Prolapse Impact Questionnaire.
*
UDI scores range from 0−300, POPDI scores range from 0−300, CRADI scores range from 0−400, UIQ scores range from 0−400, CRAIQ scores range from 0−400, POPIQ scores range from 0−400, and PFDI and PFIQ subscale scores range from 0−400 with higher scores indicating worsening symptoms. Data are mean±standard deviation unless otherwise specified.